Skip to main content
Publications
Arana A , Varas-Lorenzo C, McQuay LJ, Ziemiecki R , Bui CL , Gilsenan AW , Rothman KJ , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Margulis AV , Perez Gutthann S . Do individual antimuscarinic drugs to treat overactive bladder have different cardiovascular risks? A UK CPRD cohort study . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):534-5.
Castellsague J, Calingaert B , Rothman KJ , Gutierrez L , van Herk-Sukel MPP, Kuiper JG, Pottegard A, Hallas J, Berglind IA, Sundstrom A, Dedman D, Gallagher A, Kaye JA, Pardo C, Perez-Gutthann S . Probabilistic bias analysis for unmeasured confounders in a study of users of topical tacrolimus, pimecrolimus, and corticosteroids (JOELLE) study . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):142-3.
Castellsague J, Kuiper JJG, Pottegard A, Berglind IA, Dedman D, Gutierrez L , Calingaert B , van Herk-Sukel MPP, Hallas J, Sundstrom A, Gallagher A, Kaye JA, Pardo C, Rothman KJ , Perez-Gutthann S . Risk of lymphoma in users of topical tacrolimus, pimecrolimus and corticosteroids (JOELLE study) . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):494-5.
Castellsague J, van Herk-Sukel MPP, Hallas J, Sundstrom A, Gallagher A, Gutierrez L , Calingaert B , Kuiper JG, Pottegard A, Berglind IA, Dedman D, Kaye JA, Pardo C, Rothman KJ , Perez-Gutthann S . Risk of skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids. JOint European Longitudinal Lymphoma and skin cancer Evaluation (JOELLE) study . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):527.
Castellsague J, Calingaert B , Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Varas-Lorenzo C, Arana A , Bui C , Prados-Torres A, Gonzalez-Rubio F, Roso-Llorach A, Citarella A, Garbe E, Blenk T, Perez-Gutthann S . Characterization of new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):203-4.
Margulis A , Houben E, Olesen M, Hallas J, Overbeek J, Pottegard A, Ye W, Villegas D, Perez-Gutthann S , Arana A . Drug utilization study: evaluation of the use of nepafenac in the Netherlands and Denmark . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):225.
Margulis AV , Varas-Lorenzo C, Bui CL , McQuay LJ, Ziemiecki R , Reynolds M , Rebordosa C , Pladevall-Vila M , Fortuny J , Rivero-Ferrer E , Plana E , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS) . Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.
Margulis AV , Linder M, Arana A , Pottegard A, Anveden-Berglind I, Bui CL , Kristiansen NS, Bahmanya S, McQuay LJ, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Hallas J. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):653.
Hallas J, Margulis AV , Pottegard A, Kristiansen N, Bui CL , Krueger W, Atsma WJ, Appenteng K, Franks B, de Vogel S, D 'Silva M, Perez-Gutthann S , Arana A . Incidence of cardiovascular events in new users of overactive bladder medications in Denmark . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491.
Hallas J, Margulis AV , Pottegard A, Kaye JA, Kristiansen N, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Elevated bladder and prostate cancer rates following initiation of OAB medication: findings from the Danish Registries . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533.
Fortuny J , Kaye JA, Bui CL , Gilsenan AW , Bartsch J , Plana E , McQuay LJ, Calingaert B , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez Gutthan S , Arana A , Margulis AV . Evaluation of free-text comments to validate common cancer diagnoses in the UK CPRD . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58.
Linder M, Margulis AV , Anveden-Berglind I, Bahmanyar S, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Cardiovascular risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491-2.
Linder M, Margulis AV , Anveden-Berglind I, Bahmanyar S, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Cancer risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533-4.
Kuiper JG, van Herk-Sukel MPP, Castellsague J, Potttegard A, Berglind IA, Dedman D, Calingaert B , Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ , Perez-Gutthann S . Utilization of tacrolimus and pimecrolimus in Europe: results from the JOint European Longitudinal Lymphoma and skin cancer Evaluation (JOELLE) study . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):630-1.
Perez-Gutthann S , de Abajo F, Garcia Rodriguez LA, Varas-Lorenzo C, Gutierrez L, Castellsague J. Pharmacoepidemiology: Epidemiology applied to pharmaceutical development, safety and risk. In: Hernández G, Moreno A, Zaragoza F, Porras A, editors. MEDIPHARM: Tratado de Medicina Farmacéutica . Madrid: Spain. Médica Panamericana; 2010.